Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.

Saved in:
Bibliographic Details
Title: Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.
Authors: Meyer-Wentrup F; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Jonas SF; Biostatistics and Epidemiology Office, Gustave Roussy, INSERM U1018 Oncostat, Labelled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France., Knoerr F; Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Auperin A; Biostatistics and Epidemiology Office, Gustave Roussy, INSERM U1018 Oncostat, Labelled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France., Alexander S; Division of Hematology/Oncology/Bone Marrow Transplantation, BC Children's Hospital, The University of British Columbia, Vancouver, Canada., Andres M; Department of Pediatric Hematology and Oncology, University Hospital La Fe of Valencia, Valencia, Spain., Attarbaschi A; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.; Department of Pedatric Hematology and Oncology, St. Anna Children's Cancer Research Institute, Vienna, Austria., Burke GAA; Cancer Research UK Clinical Trials Unit, School of Medical Sciences, The University of Birmingham, Birmingham, United Kingdom., Burkhardt B; Department of Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany., Ceppi F; Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department of Woman-Mother-Child, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland., Gross T; Department of Pediatric Hematology and Oncology, Phoenix Children's Hospital, Phoenix, AZ., Kabickova E; Department of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic., Klapper W; Department of Hematopathology, University Medical Center Kiel, Kiel, Germany., Miles RR; Department of Pathology, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Taj M; Department of Pediatrics, The Royal Marsden NHS Foundation Trust, London, United Kingdom., Zimmermann M; Department of Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany., Minard-Colin V; Departments of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.; INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France., Woessmann W; Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Source: Blood advances [Blood Adv] 2026 Jun 23; Vol. 10 (12), pp. 4370-4374.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025019553